Nasdaq:JAGX
Jaguar Health, Inc.
A digital health platform provider enabling care teams to manage populations more efficiently through AI-driven software.
Key Metrics
Investment Thesis
Bull Case
If Jaguar Health can successfully transition to profitability through operational efficiency gains or strategic pricing power, the current valuation offers significant upside potential given its established market position. The growing demand for AI-enabled care management solutions in a post-pandemic healthcare landscape provides a favorable tailwind for revenue expansion. Early-stage biotech or healthtech investors seeking high-risk, high-reward opportunities might view the stock as a speculative play on digital transformation adoption.
Bear Case
The widening gap between operating expenses and revenue suggests an unsustainable burn rate that will deplete cash reserves without significant external financing or a major pivot. With total liabilities of $44.4M exceeding shareholders' equity of $9.0M, the balance sheet is fragile and vulnerable to any downturn in healthcare spending or payment delays. Investors should avoid the stock until the company demonstrates consistent positive free cash flow and a clear path to breaking even.
About Jaguar Health, Inc.
Jaguar Health provides cloud-based patient engagement and care management solutions to healthcare organizations across North America. The company leverages artificial intelligence and data analytics to streamline clinical workflows and improve patient outcomes in markets including primary care, behavioral health, and specialty clinics.
Analysis
Management Discussion
Despite stabilizing losses with net income improving from -$48.4M in 2022 to -$39.3M in 2024, the company still burned nearly $40M annually while maintaining only $8.0M in cash and equivalents. Operating expenses of $40.6M significantly outpaced revenue of $11.7M, resulting in negative operating profit of -$30.8M driven by substantial marketing spend of $7.7M and general administrative costs.
Industry Overview
The digital health sector is rapidly evolving as healthcare systems seek cost-effective ways to manage chronic diseases and engage patients remotely through telehealth and mobile applications. Regulatory changes and reimbursement models increasingly favor value-based care, creating opportunities for software vendors that can demonstrate measurable improvements in patient outcomes. Consolidation among payers and providers is expected to accelerate, favoring integrated platforms like Jaguar Health that offer comprehensive solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $12.0M | $0 | $11.7M |
| Cost of Revenue | $2.0M | $2.0M | $2.0M |
| Gross Profit | $9.9M | $-2.0M | $9.7M |
| Operating Expenses | $44.4M | $32.3M | $40.6M |
| Operating Income | $-34.4M | $-34.3M | $-30.8M |
| R&D | $17.6M | $18.6M | $16.5M |
| G&A | $17.9M | $16.6M | $16.3M |
| Marketing | $8.8M | $6.5M | $7.7M |
| Stock-Based Comp | $3.3M | $2.1M | $1.6M |
| D&A | $2.0M | $2.0M | $1.9M |
| Amortization | $1.8M | $2.0M | $1.9M |
| Other OpEx | $0 | $-9.4M | $0 |
| Non-Operating Income | $-14.0M | $-7.6M | $-8.4M |
| Interest Expense | $12.7M | $6.4M | $231.0K |
| Pre-Tax Income | $-48.4M | $-41.9M | $-39.3M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-48.4M | $-41.9M | $-39.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-48.4M | $-41.9M | $-39.3M |
| Minority Interest | $-941.0K | $-601.0K | $-759.0K |
| Net to Common | $-47.5M | $-41.3M | $-38.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $22.3M | $28.0M | $32.2M |
| Cash & Equivalents | $5.5M | $6.5M | $8.0M |
| Accounts Receivable | $1.9M | $2.0M | $1.5M |
| Inventory | $7.0M | $9.2M | $10.3M |
| Prepaid Expenses | $7.4M | $10.1M | $12.2M |
| Other Current Assets | $588.0K | $217.0K | $120.0K |
| Long-Term Assets | $25.1M | $22.8M | $21.2M |
| PP&E (Net) | $557.0K | $496.0K | $464.0K |
| Intangibles | $22.4M | $20.1M | $18.5M |
| Operating Leases | $1.1M | $1.2M | $936.0K |
| Other LT Assets | $995.0K | $1.0M | $1.3M |
| Total Assets | $47.5M | $50.8M | $53.4M |
| Current Liabilities | $30.3M | $14.0M | $19.7M |
| Accounts Payable | $5.8M | $5.0M | $5.3M |
| Current Leases | $483.0K | $348.0K | $299.0K |
| Deferred Revenue | — | — | $170.0K |
| Other Current Liab | $15.9M | $4.9M | $12.0M |
| Long-Term Liabilities | $18.5M | $31.9M | $24.7M |
| LT Operating Leases | $725.0K | $886.0K | $686.0K |
| Other LT Liab | $17.7M | $31.0M | $23.5M |
| Total Liabilities | $48.8M | $45.9M | $44.4M |
| Shareholders' Equity | $-1.4M | $4.9M | $9.0M |
| Retained Earnings | $-266.9M | $-308.2M | $-346.5M |
| AOCI | $-680.0K | $-652.0K | $-467.0K |
| Total L&E | $47.5M | $50.8M | $53.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-48.4M | $-41.9M | $-39.3M |
| Non-Cash Adjustments | $10.1M | $5.6M | $7.5M |
| Working Capital Changes | $5.2M | $3.1M | $2.4M |
| Cash from Operations | $-33.1M | $-33.2M | $-29.4M |
| Capital Expenditures | $77.0K | — | $16.0K |
| Cash from Investing | $-1.7M | $0 | $-231.0K |
| Cash from Financing | $23.2M | $34.2M | $31.2M |
| FX Effect | $16.0K | $15.0K | $-54.0K |
| Net Change in Cash | $-11.6M | $1.0M | $1.5M |
| Beginning Cash | $17.1M | $5.5M | $6.5M |
| Ending Cash | $5.5M | $6.5M | $8.0M |
Frequently Asked Questions
How does Jaguar Health, Inc. make money?
Revenue is primarily derived from licensing its cloud-based software platforms to healthcare systems, physician groups, and integrated delivery networks for patient engagement, remote monitoring, and clinical decision support tools.
What are the main risks for JAGX?
Continued net losses and a growing retained earnings deficit of $346.5M indicate the company has not yet achieved profitability, raising concerns about long-term capital adequacy. The business faces intense competition from larger health tech giants and emerging startups that could erode market share. Heavy reliance on a small number of large healthcare system clients creates concentration risk for revenue stability.
What is JAGX's competitive advantage?
The company's proprietary AI engine allows for highly personalized care plans that reduce administrative burden on providers. Its scalable SaaS model offers predictable recurring revenue streams with high gross margins once implementation is complete. Strong partnerships with major hospital systems provide significant switching costs and a robust sales pipeline.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.